Under the auspices of the Ministry of Health of the Russian Federation
Participation is free
25 March 2022
Online
About the conference
Principal directions: (Key trends)
- Scientific breakthrough in cardiology amid the COVID-19 pandemic: groundbreaking research findings in 2020-2021 and 2022.
- Effects of sodium glucose cotransporter (SGLT2) inhibitors on risk of death and rate of hospitalization in patients with chronic heart failure in the EMPA-REG OUTCOME study.
- The use of ARNI in the treatment of patients with arterial hypertension and chronic heart failure in the PARADIGM-HF study.
- Effects of combined lipid-lowering therapy (statin + ezetimibe or statin + fenofibrate) in studies: ENHANCE, I-ROSETTE, SAFARI.
- The use of anticoagulants in the post-COVID period (studies by MICHELLE and EINSTEIN-Jr).
- Treatment algorithms for chronic kidney disease – current research, practical recommendations for day-to-day practices.
- Issues of prescribing new medications in the treatment of arterial hypertension: identification of indications, dose selection and therapy regimen correction.
- Selecting basic combined lipid-lowering treatment – latest research results, new opportunities.
- Use of hormonal and targeted therapy for COVID-19.
- New dosage forms in therapy for type II diabetes mellitus.
- Vaccination in 2022: new steps to enhance the efficiency of the population immunization.
- Laboratory diagnostics in the post-COVID period – tools and points of application.
During the conference
01
Symposia
02
Workshops
Moderators:
G.E. Gendlin, N.G. Poteshkina, A.V. Melekhov
- Heart failure in COVID-19: do all questions have an answer?
- N.G. Poteshkina
- Patients with COVID-19 at the hospital and post-hospital period – do they need a heart check-up?
- G.E. Gendlin
- Post-Covid syndrome
- A.V. Melekhov
Moderator:
G.P. Arutyunov
Moderator:
A.G. Arutyunov
- Two years of COVID-19, the experience of 7 countries
- E.I. Tarlovskaya
- Omicron: The differences in the clinical picture. Does the risk remain?
- A.G. Arutyunov
- Targeted therapy in the treatment of COVID-19 – data for 2022
- S.N. Avdeev
- Monoclonal antibodies in the treatment of COVID-19
- D.S. Fomina
Moderator:
A.G. Arutyunov
- Management strategies for patients with hypertension during the pandemic
- O.D. Ostroumova
- A patient after COVID-19 as a new risk category
- A.G. Arutyunov
- Antibiotic-associated colitis in Post-COVID
- N.V. Bakulina, O.I. Solovieva
- Rehabilitation after COVID-19. Experience of the Republic of Armenia
- Lamara Manukyan
(sponsored by Sanofi)
Moderator:
M.V. Ezhov
- Dyslipidemia 2022: key trends and innovative solutions
- M.V. Ezhov
- The role of general practitioner in lipid storage disease management in patients with high and very high CV risk
- A.G. Arutyunov
- New opportunities in lipid-lowering therapy intensification
- Yu.A. Karpov
- Opportunities in the routing organization and effective treatment in patients with ACS: the place of PCSK9i
- A.Yu. Lebedeva
(sponsored by AstraZeneca)
Moderator:
A.G. Arutyunov
- A change navigator, focus on early diagnosis of patients with CKD
- T.V. Adasheva
- The birth of the future: DAPA-CKD as revolution of ideas in CKD patients management
- O.Yu. Sukhareva
- Caring for the heart: Findings from the DAPA-CKD trial in patients with cardiovascular diseases
- S.V. Villevalde
(sponsored by Boehringer Ingelheim)
Moderator:
G.P. Arutyunov
- Heart failure with reduced ejection fraction – the importance of nephroprotective therapy
- M. Batyushin
- When do we start therapy for heart failure with SGLT2 inhibitors: inpatient or outpatient?
- G. Arutyunov
- Type 2 diabetes and heart failure. How to sail between Scylla and Charybdis without a loss?
- Yu.Sh. Khalimov
- Practical aspects of iSGLT2 use when administered without type 2 diabetes mellitus
- I.В. Zhirov
Moderator:
O.N. Dzhioeva
- A patient with thrombosis: diversity of the problem and unity of solution
- O.N. Dzhioeva
- Oral GLP-1 receptor agonists: new perspectives
- Sarantis LIvadas (Athens)
- Therapy to prevent deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with CHF (congestive heart failure) – new steps in 2022
- Akhmetzhan Sugraliev
Speakers
Partners
If you have any questions about
cooperation, please contact us at the
following address
About the Association
The Eurasian Association of Internal Medicine is an independent association that provides an opportunity for its members to share experience and discuss crucial problems of evidence-based medicine and clinical practice.
Among the Association’s main goals is to disseminate information about ground-breaking research in the field of internal medicine.
The Association holds free events for medical specialists letting them earn CME credit points.
Medical specialists may become members of the EAT’s expert community and get access to
more materials on the Association’s website
FAQ
This event is organized for medical professionals: practicing physicians, residents, medical students.
Participation is free.
The broadcast can be viewed on this website. It will be available on the day of the conference – March 25, 2022.